Straumann N

The Straumann share initially opened noticeably higher but reversed intraday and traded around 102 CHF after Deutsche Bank downgraded its rating to "Hold" and cut the price target from 119 to 99 CHF. The bank cited a high valuation (about 26× expected 2027 earnings) and execution risk around the upcoming CEO change. JPMorgan, Barclays and BMO remained largely constructive (JPMorgan raised its target to 136 CHF), but the divergent analyst views are weighing on a recovery. Straumann had previously reported 8.5% organic revenue growth for Q2 and raised its forecast for core EBIT margin improvement by 140–170 basis points. » Más en de.investing.com

Straumann confirms an ambitious growth path and has recently significantly raised its margin targets. For H1 2026 the AWP analyst consensus is for sales of 1'375 Mio. CHF, organic growth of 7.4% and a core-EBIT margin of around 25.4%. Particular attention is being paid to regional developments; analysts see further potential, but the stock has so far shown only limited momentum. » Más en finanzen.net

Straumann reports an upward revision to its guidance and has reached a 52-week high, giving trend followers a fresh buy signal. Market participants are rotating capital out of strong-performing sectors into more defensive stocks, which could benefit healthcare names and especially Straumann. The group is also undergoing a transformation process that should justify further upside potential in the share price. » Más en finanzen.net

A purchase of Straumann shares ten years ago for 1,000 CHF would today amount to 26.11 shares and be worth 2,765.01 CHF at a price of 105.90 CHF (as of July 2, 2026). This corresponds to a performance of +176.50 percent. The market capitalization of all Straumann shares is 17.32 billion CHF; stock splits and dividends were not taken into account in the calculation. » Más en finanzen.net

Straumann shares suffered their biggest daily loss since April after disappointing quarterly results and a weaker outlook from US competitor Align Technology were released. Analysts see ongoing weakness in the US market as a key risk for the sector, but highlight differences in product mix and Straumann's previous outperformance. Straumann is set to report its own quarterly results on August 13. » Más en de.investing.com